We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.

$AVXL Australia trial data meets the gold standard.

$AVXL - Alz Topline Data was solid ..

Efficacy is likey overwhelming after seeing 👀 data details!

$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Now DATA met expectations.

Also clint said every time Blarcamesine data comes back it looks better and better. .

Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!

So I think the data so far was encouraging,

$NVAX Let's Gooooooooo 😂 Thanks to the Biden administration for good Jobless data yesterday.

Data good.

They’re soaring after hours with RSV data.

but should be safer and more durable safer so far by looks of taiwans vaers data

but the data speaks for the reality of 2373, not inferior in any way, especially breadth and durability

$NVAX macro data seems to be good for the market!

It’s protein conventional vaccs that are the true effective and safe ones with long term data to back it up.

With all the evidence and data available, this stock is going to rise and shine like a supernova.

Fda recognizing their pcv data as a breakthrough 👇🏻 bodes well for lil ole gritty which as we know has a pcv on steroids with our own randomized data coming this year lfgggg

This will help build the biopharma oncology business greatly, as it will gain even more valuable data here.

Up 100% on Biomarker data.

$MRNA Moderna Extends Gains Pre-market on Strong mRNA-1345 Data https://whatstocksmove.com/mrna-moderna-extends-gains-pre-market-on-strong-mrna-1345-data/574/

$ARKG Moderna up about 6% after hours on GREAT data for Phase 3 .

Following review by an independent Data and Safety Monitoring Board, the primary efficacy endpoints have been met, including vaccine efficacy of 83.7% against RSV-associated lower respiratory tract disease as defined by two or more symptoms.

$VERU $KALA $XBI $MRNA SABIZABULIN data are resounding, outstanding drug, works great, will save millions of people from death, FDA and EMA what are you waiting for??!

$MRNA very exciting data and validation of $GRTS thesis.

The trial data suggests that the treatment is safe and well-tolerated by patients, and it has shown encouraging signs of efficacy.

REFILE-US STOCKS-Wall St rises after CPI data